Citigroup Inc Erasca, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Citigroup Inc holds 134,367 shares of ERAS stock, worth $318,449. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,367

Previous 48,701 175.9%

Holding current value

$318,449

Previous $114,000 221.05%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.17 - $3.28 $185,895 - $280,984	85,666 Added 175.9%	134,367 $366,000
Q2 2024 Aug 12, 2024	BUY	$1.79 - $2.63 $58,917 - $86,566	32,915 Added 208.51%	48,701 $114,000
Q1 2024 May 10, 2024	BUY	$1.67 - $2.55 $2,601 - $3,972	1,558 Added 10.95%	15,786 $32,000
Q4 2023 Feb 09, 2024	BUY	$1.67 - $2.49 $20,310 - $30,283	12,162 Added 588.67%	14,228 $30,000
Q3 2023 Nov 09, 2023	SELL	$1.97 - $2.91 $67,639 - $99,914	-34,335 Reduced 94.32%	2,066 $4,000
Q2 2023 Aug 10, 2023	BUY	$2.57 - $3.3 $85,072 - $109,236	33,102 Added 1003.39%	36,401 $100,000
Q1 2023 May 11, 2023	SELL	$2.74 - $4.44 $341,012 - $552,589	-124,457 Reduced 97.42%	3,299 $9,000
Q4 2022 Feb 09, 2023	BUY	$3.89 - $8.57 $175,018 - $385,581	44,992 Added 54.36%	127,756 $550,000
Q3 2022 Nov 10, 2022	BUY	$5.82 - $10.68 $438,117 - $803,969	75,278 Added 1005.58%	82,764 $646,000
Q2 2022 Aug 10, 2022	BUY	$4.58 - $8.72 $2,835 - $5,397	619 Added 9.01%	7,486 $42,000
Q1 2022 May 12, 2022	SELL	$8.6 - $15.48 $23,340 - $42,012	-2,714 Reduced 28.33%	6,867 $59,000
Q4 2021 Feb 10, 2022	BUY	$12.51 - $22.75 $90,372 - $164,346	7,224 Added 306.49%	9,581 $149,000
Q3 2021 Nov 10, 2021	BUY	$17.43 - $24.34 $41,082 - $57,369	2,357 New	2,357 $50,000

Others Institutions Holding ERAS

# of Institutions

140

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $289M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account